Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Mevo Health vs Velvet Rx

Mevo Health
Graded #327

Higher grade

vs+2.1000000000000014
Velvet Rx
Graded #381

Lower grade

The verdict

Mevo Health takes it — 60.2/100 to 58.1/100.

Mevo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mevo Health (Mevo Health LLC, Delaware) is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral-tablet forms — a rare both-routes, both-molecules menu.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMevo Health +14
56
42
Dose & formulationMevo Health +8
83
75
Clinical oversightEven
67
67
Labs & monitoringVelvet Rx +1
52
53
FulfillmentEven
57
57
Contract termsVelvet Rx +35
20
55
Mevo Health · left barVelvet Rx · right bar

The numbers

MetricMevo HealthVelvet Rx
WeighScore60.2/10058.1/100
GradeCC
Scorecard rank#327#381
Semaglutide$199/mo (all doses, compounded)$299/mo (compounded)
Tirzepatide$259/mo (all doses, compounded)$359/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Mevo Health

Graded #327 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed
Velvet Rx

Graded #381 · C

Strengths

  • Public pricing across 3 SKUs (semaglutide $299, tirzepatide $359, oral GLP-1 $349) — uncommon in compounded telehealth
  • First-month promo pricing shown upfront ($139 sema / $199 tirz / $189 oral)
  • Single monthly price includes consult, prescription, 4 weeks of medication, and free 1–2 day shipping
  • FSA/HSA eligible
  • Three options under one roof: injectable sema, injectable tirz, and an oral GLP-1

Where it loses points

  • Oral GLP-1 SKU doesn't name the specific drug — a real gap given Rybelsus, Foundayo, and compounded oral semaglutide differ clinically
  • No LegitScript or NABP .pharmacy seal displayed
  • No legal entity name disclosed
  • No physical address disclosed
  • Compounding pharmacy partner not named

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard